Biodexa Pharmaceuticals Plc (BDRX) News
Track canonical SquawkNews coverage tagged to BDRX, Biodexa Pharmaceuticals Plc. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Biodexa Pharmaceuticals PLC (BDRX) Says eRapa Phase 3 Is Over 50% Enrolled; Futility Read in Q1 2027
Biodexa Pharmaceuticals PLC reported its Phase 3 eRapa trial in FAP is over 50% enrolled across 29 U.S./EU centers, with an interim futility analysis expected in Q1 2027. The program has FDA/EMA Orphan Drug status and $2
REGULATION | Sep 23, 2026, 10:33 AM UTC
L
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
Today's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC NASDAQ:BDRX is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which t
NEWS | Sep 23, 2026, 10:31 AM UTC
L
BDRX - The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
BDRX - The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
NEWS | Sep 23, 2026, 10:30 AM UTC
L
Biodexa Pharmaceuticals enters warrant exercise transaction for $2.3M gross proceeds; shares rise
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
EQUITY | Sep 15, 2026, 12:31 PM UTC
L
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) Raises ~$2.3M Via Warrant Exercise, Issues New Warrants
Biodexa entered a warrant exercise agreement for ~$2.3M gross cash as an investor exercises 2,204,218 ADS warrants at $1.05. In return, Biodexa will issue new unregistered warrants for up to 4,408,436 ADSs at $1.05, exer
NEWS | Sep 15, 2026, 12:03 PM UTC
L
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsSeptember 15, 2026Biodexa Pharmaceuticals PLC, NASDAQ:BDRX (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company devel
NEWS | Sep 15, 2026, 12:03 PM UTC
L
BDRX - Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
BDRX - Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
NEWS | Sep 15, 2026, 12:00 PM UTC
L
Interim results for the six months ended June 30, 2026
September 11, 2026Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Interim results for the six months ended June 30, 2026Biodexa Pharmaceuticals PLC NASDAQ:BDRX, a clinical-stage biopharmaceutical company developin
NEWS | Sep 11, 2026, 08:32 PM UTC
L
BDRX - Interim results for the six months ended June 30, 2026
BDRX - Interim results for the six months ended June 30, 2026
NEWS | Sep 11, 2026, 08:30 PM UTC
L
Biodexa Pharmaceuticals expected to post breakeven results
Biodexa Pharmaceuticals PLC is expected to post breakeven results per share, according to an earnings preview.
EARNINGS | Sep 08, 2026, 11:01 AM UTC
L
JOYY rises in premarket after quarterly results
JOYY shares rose 3.6% in premarket trading after the company reported second-quarter earnings of $1.24 per share versus $1.28 expected and sales of $590.754 million versus $574.118 million expected.
EARNINGS | Aug 26, 2026, 09:22 AM UTC
M
Biodexa announces milestone in Serenta Phase 3 FAP trial
Biodexa announces a major milestone for its Serenta registrational Phase 3 trial in FAP, with no further details or catalyst supplied in the alert.
EQUITY | Aug 19, 2026, 12:30 PM UTC
L
BDRX Holds General Meeting
BDRX holds general meeting
EQUITY | Jul 29, 2026, 08:30 PM UTC
L
BDRX Initiates FAP Support in France
BDRX starts support for FAP patients
EQUITY | Jul 29, 2026, 12:30 PM UTC
L
BDRX Biodexa Pharmaceuticals - files for resale of 2.56M adss by selling shareholders - SEC filing
BDRX Biodexa Pharmaceuticals - files for resale of 2.56M adss by selling shareholders - SEC filing
REGULATION | Jul 15, 2026, 08:13 PM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
H
Select Premarket Movers
Upside: -AVAV +35% (earnings, guidance) -VWAV +29% (acquires 51% controlling interest in private Israeli aerospace and defense company Meteor Aerospace for ~$20.4M in stock) -SEDG +11% (solar stock strength following FCC
GEOPOLITICS | Jun 30, 2026, 12:26 PM UTC
L
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Abivax (NASDAQ: ABVX ) shares increased by 36.0% to $130.74 during Tuesday's pre-market session. The company's market cap stands at $7.6 billion. Cuprina Holdings (Cayman) (NASDAQ: CUPR ) shares moved upwards by
EQUITY | Jun 30, 2026, 12:05 PM UTC
L
Biodexa Pharmaceuticals shares are trading lower after the company announced the pricing of its $3.5 million offering and concurrent private
Biodexa Pharmaceuticals shares are trading lower after the company announced the pricing of its $3.5 million offering and concurrent private placement of pre-funded warrants and warrants.
EQUITY | Jun 30, 2026, 12:04 PM UTC
L
Biodexa Prices $3.5M Offering And Concurrent Private Placement Of 282,952 Shares At $2.85/ADS.
Biodexa Prices $3.5M Offering And Concurrent Private Placement Of 282,952 Shares At $2.85/ADS.
EQUITY | Jun 30, 2026, 12:03 PM UTC